From: Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma
 | Age-adjusted | Multivariablea | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
a) Overall survival (OS) | ||||
 Stage | ||||
  II vs. I | 2.13 (0.96–4.73) | 0.064 NS |  |  |
  III vs. I | 2.79 (1.30–5.95) | 0.008 |  |  |
  IV vs. I | 4.52 (2.12–9.64) | < 0.001 |  |  |
 Viral status | ||||
  HPV-pos vs. EBV-pos | 1.62 (0.88–3.00) | 0.123 NS |  |  |
  HPV/EBV-neg vs. EBV-pos | 2.67 (1.64–4.34) | < 0.001 |  |  |
 TLR1 | ||||
  Mild vs. neg | 0.30 (0.09–1.04) | 0.057 NS | 0.69 (0.18–2.70) | 0.595 NS |
  Strong vs. neg | 0.24 (0.08–0.79) | 0.018 | 0.48 (0.14–1.70) | 0.256 NS |
 TLR2 nuclear | ||||
  Mild vs. neg | 0.56 (0.25–1.24) | 0.151 NS | 0.53 (0.23–1.19) | 0.125 NS |
  Strong vs. neg | 0.62 (0.27–1.45) | 0.271 NS | 0.52 (0.21–1.30) | 0.162 NS |
 TLR2 cytoplasmic | ||||
  Mild vs. neg | 0.62 (0.27–1.41) | 0.256 NS | 0.49 (0.20–1.17) | 0.109 NS |
  Strong vs. neg | 0.70 (0.31–1.55) | 0.373 NS | 0.68 (0.30–1.56) | 0.363 NS |
 TLR4 | ||||
  Mild vs. neg | 1.16 (0.51–2.65) | 0.727 NS | 1.07 (0.46–2.50) | 0.872 NS |
  Moderate/strong vs. neg | 1.15 (0.52–2.55) | 0.731 NS | 1.13 (0.50–2.56) | 0.775 NS |
 TLR5 | ||||
  Mild vs. neg | 0.75 (0.45–1.24) | 0.259 NS | 0.65 (0.38–1.10) | 0.108 NS |
  Strong vs. neg | 1.37 (0.80–2.33) | 0.250 NS | 0.88 (0.47–1.61) | 0.666 NS |
 TLR7 | ||||
  Mild vs. neg | 0.28 (0.12–0.64) | 0.003 | 0.37 (0.16–0.84) | 0.018 |
  Moderate/strong vs. neg | 0.49 (0.23–1.04) | 0.062 NS | 0.44 (0.20–0.95) | 0.038 |
 TLR9 | ||||
  Mild vs. neg | 0.21 (0.07–0.60) | 0.004 | 0.37 (0.12–1.16) | 0.087 NS |
  Strong vs. neg | 0.32 (0.12–0.92) | 0.034 | 0.49 (0.17–1.46) | 0.199 NS |
b) Disease-specific survival (DSS) | ||||
 Stage | ||||
  II vs. I | 2.50 (0.68–9.14) | 0.166 NS |  |  |
  III vs. I | 4.72 (1.40–15.95) | 0.013 |  |  |
  IV vs. I | 8.63 (2.59–28.80) | < 0.001 |  |  |
 Viral status | ||||
  HPV-pos vs. EBV-pos | 1.10 (0.49–2.47) | 0.822 NS |  |  |
  HPV/EBV-neg vs. EBV-pos | 2.22 (1.25–3.96) | 0.007 |  |  |
 TLR1 | ||||
  Mild vs. neg | 0.50 (0.11–2.25) | 0.369 NS | 1.30 (0.26–6.57) | 0.748 NS |
  Strong vs. neg | 0.32 (0.08–1.32) | 0.113 NS | 0.76 (0.17–3.43) | 0.720 NS |
 TLR2 nuclear | ||||
  Mild vs. neg | 0.75 (0.26–2.10) | 0.578 NS | 0.88 (0.31–2.52) | 0.811 NS |
  Strong vs. neg | 0.84 (0.28–2.54) | 0.757 NS | 1.05 (0.33–3.34) | 0.937 NS |
 TLR2 cytoplasmic | ||||
  Mild vs. neg | 0.62 (0.23–1.65) | 0.336 NS | 0.69 (0.25–1.90) | 0.468 NS |
  Strong vs. neg | 0.71 (0.28–1.84) | 0.481 NS | 0.89 (0.33–2.34) | 0.806 NS |
 TLR4 | ||||
  Mild vs. neg | 1.52 (0.54–4.41) | 0.441 NS | 1.65 (0.56–4.88) | 0.368 NS |
  Moderate/strong vs. neg | 1.12 (0.40–3.20) | 0.827 NS | 1.28 (0.44–3.73) | 0.652 NS |
 TLR5 | ||||
  Mild vs. neg | 0.87 (0.47–1.61) | 0.665 NS | 0.81 (0.43–1.53) | 0.518 NS |
  Strong vs. neg | 1.62 (0.85–3.06) | 0.141 NS | 1.34 (0.64–2.80) | 0.442 NS |
 TLR7 | ||||
  Mild vs. neg | 0.28 (0.11–0.70) | 0.006 | 0.39 (0.15–0.98) | 0.046 |
  Moderate/strong vs. neg | 0.47 (0.21–1.05) | 0.067 NS | 0.47 (0.21–1.09) | 0.079 NS |
 TLR9 | ||||
  Mild vs. neg | 0.27 (0.08–0.93) | 0.038 | 0.54 (0.15–1.98) | 0.351 NS |
  Strong vs. neg | 0.39 (0.12–1.29) | 0.123 NS | 0.70 (0.20–2.43) | 0.576 NS |